Status:
COMPLETED
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
Lead Sponsor:
Ziekenhuis Oost-Limburg
Conditions:
NAFLD (Nonalcoholic Fatty Liver Disease)
Polycystic Ovarian Syndrome (PCOS)
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
Eligibility Criteria
Inclusion
- Adults (i.e. older than 18 years of age)
- The diagnosis of PCOS based on expert opinion (i.e. according to Rotterdam criteria)
- Able to understand patients information concerning this study
- Able to give written informed consent
Exclusion
- Excessive alcohol use: ≥ 2u (20g)/day for females
- Exclusion of other causes of liver disease
- Secondary causes of liver steatosis
- Other causes of endocrinological disease
- Diseases that might mimic PCOS
Key Trial Info
Start Date :
November 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT07146815
Start Date
November 29 2022
End Date
April 1 2025
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium, 3600